Onesource Specialty pivots on DDC MSAs, accelerates soft gel timeline
Q1 revenue up 37% to ₹4,490 mn, but management's strategy reversal and shortened capacity fill raise guidance credibility questions.
What's new
- Q1 FY27 revenue ₹4,490 mn, up 37% YoY; EBITDA ₹1,233 mn, up 39% YoY.
- Semaglutide commercialization in Canada with two partners; >40% of India's generic pens produced at site.
- Second DDC cartridge line commercializing this quarter; another within FY27.
- Soft gelatin added capacity expected fully utilized in 12-15 months, down from previous ~2 years.
Themes from the call
Demand
DDC capacity is full, driven by Semaglutide, new MSA contracts, and GLP customer wins; biologics RFP funnel nearly 4x year-ago level.
Margins
EBITDA margin improved to ~27.5%, attributed to higher DDC mix; FY28 target of 40% reiterated, contingent on capacity ramp and fixed cost absorption.
Capital allocation
~$100 mn multi-site capex, 80% committed, mostly for DDC; biologics capex expected significantly lower; injectables site shutdown in Q2 for prefilled syringe and lyophilization.
Guidance watch
- FY28 organic revenue $400 mn and 40% EBITDA margin reiterated; new DDC lines to drive sequential revenue and EBITDA improvement from H2 FY27.
- Soft gelatin capacity fully utilized in 12-15 months; greenfield project update expected next quarter.
- Injectable site shutdown in Q2 and next quarter; new capabilities to become significant FY30 contributor.
- Biologics development MSAs to convert to commercial revenues from FY29 onwards.
Risk flags
- DDC MSA strategy reversal unexplained; prior focus on commercial sales now includes MSAs as a key driver.
- Soft gel timeline acceleration without identifiable operational or demand change; no current utilization percentage disclosed.
- No line-level margin bridge or explicit conditions on FY28 $400 mn target; dependencies on customer launches and geopolitical factors.
Key quotes
-
"We remain confident and are happy to reiterate our FY28 outlook of 400 million in organic revenue, as well as EBITDA margins of 40.0%"
— Neeraj, prepared remarks -
"We could have continued to accept MSAs from new customers, but we decided to prioritize our capacities for commercial sales."
— Management, Jan 2026 call
The brief
Onesource Specialty's Q1 numbers look strong: revenue up 37% to ₹4,490 mn, EBITDA up 39% to ₹1,233 mn, and capacity running full. The drug-device combination platform is delivering, with Semaglutide commercialized in Canada and two partners launched. Management reiterated its FY28 target of $400 mn organic revenue and 40% EBITDA margins. But the call carried two unexplained shifts that demand attention. In January, management said it had deliberately stopped accepting new DDC master service agreements to prioritize commercial sales. Six months later, new MSA contracts are a headline growth driver. No explanation was offered for the pivot, leaving investors to wonder whether the earlier strategy was abandoned or the current one is overstated. Separately, the timeline for filling the expanded soft gelatin capacity has been compressed from roughly two years to 12-15 months with no operational catalyst identified. The acceleration could reflect stronger demand, but without a utilization percentage or a clear bridge, it reads as an assumption rather than a forecast. The broad capacity story remains intact — three DDC lines coming online by FY28, a biologics funnel expanding fourfold, and new injectable capabilities — but the credibility of management's guidance depends on consistency and transparency. Until these two shifts are reconciled, the reiterated $400 mn and 40% margin target carries more execution risk than the headline suggests.
Onesource's capacity story is promising, but unexplained strategy pivots and timeline accelerations demand clarity before guidance can be fully underwritten.